OTCMKTS:INTI

Inhibitor Therapeutics (INTI) Stock Price, News & Analysis

Inhibitor Therapeutics logo
$0.08 0.00 (0.00%)
As of 11/13/2026

About Inhibitor Therapeutics Stock (OTCMKTS:INTI)

Advanced

Key Stats

Today's Range
$0.08
▼
$0.08
50-Day Range
$0.06
▼
$0.11
52-Week Range
$0.04
▼
$0.12
Volume
1 shs
Average Volume
14,653 shs
Market Capitalization
$13.90 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Inhibitor Therapeutics is a development-stage pharmaceutical company focused on investigating treatments for cancer. Its work includes repurposing itraconazole, an established antifungal medicine, for potential use in cancer treatment.

The company has pursued development of itraconazole for prostate cancer and basal cell carcinoma. These are investigational uses; itraconazole’s existing approval as an antifungal does not mean it is approved to treat cancer.

AI Generated. May Contain Errors.

Inhibitor Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
3rd Percentile Overall Score

INTI MarketRank™: 
0.130705944795 of 5 stars

Inhibitor Therapeutics scored higher than 3% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    There is not enough analysis data for Inhibitor Therapeutics.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Inhibitor Therapeutics is -8.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Inhibitor Therapeutics is -8.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Percentage of Shares Shorted

    0.00% of the float of Inhibitor Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Inhibitor Therapeutics has a short interest ratio ("days to cover") of 0.01, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Inhibitor Therapeutics has recently increased by 100.00%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Inhibitor Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Inhibitor Therapeutics does not have a long track record of dividend growth.

  • News Sentiment

    Inhibitor Therapeutics has a news sentiment score of -1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.59 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Inhibitor Therapeutics this week, compared to 0 articles on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, Inhibitor Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    27.80% of the stock of Inhibitor Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Inhibitor Therapeutics has minimal institutional ownership at this time.

  • Read more about Inhibitor Therapeutics' insider trading history.
Receive INTI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Inhibitor Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

INTI Stock News Headlines

My $247 scanner for $7
Bill Poulos is cutting the price of his $247 Instant Scanner to $7 for Black Friday. It's a one-time payment that covers a full year, with no subscription and no re-bills. Every night after the close, the scanner screens nearly a thousand of America's biggest stocks. It returns a short list of qualifying setups with the exact buy price next to each one. There's nothing to install. If you decide it's not for you, you get the $7 back and keep the scanner for the year.tc pixel
See More Headlines

INTI Stock Analysis - Frequently Asked Questions

Inhibitor Therapeutics' stock was trading at $0.0450 at the start of the year. Since then, INTI stock has increased by 77.8% and is now trading at $0.08.

Inhibitor Therapeutics, Inc. (OTCMKTS:INTI) posted its quarterly earnings results on Wednesday, March, 25th. The company reported ($0.01) EPS for the quarter.

Shares of INTI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

Today
11/16/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Industry
Pharmaceuticals
Sub-Industry
Pharmaceuticals
Current Symbol
OTCMKTS:INTI
CIK
1042418
Employees
1
Year Founded
1992

Profitability

EPS (Trailing Twelve Months)
($0.01)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$3.30 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
-171.44%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
3.36
Quick Ratio
3.36

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($0.01) per share
Price / Book
-8.00

Miscellaneous

Outstanding Shares
173,790,000
Free Float
125,478,000
Market Cap
$13.90 million
Optionable
Not Optionable
Beta
-0.73

Social Links

7 Best Space Stocks to Own in 2026 Cover

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

This page (OTCMKTS:INTI) was last updated on 11/13/2026 by MarketBeat.com Staff.
From Our Partners